(Q47320279)

13 January 2018

title

Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients (English)

1 reference

13 January 2018

0 references

1 reference

V Ricca

1

1 reference

13 January 2018

E Mannucci

2

1 reference

13 January 2018

M Di Bernardo

3

1 reference

13 January 2018

S M Rizzello

4

1 reference

13 January 2018

P L Cabras

5

1 reference

13 January 2018

C M Rotella

6

1 reference

13 January 2018

publication date

1 December 1996

1 reference

13 January 2018

Journal of Endocrinological Investigation

published in

1 reference

13 January 2018

volume

19

1 reference

13 January 2018

issue

11

1 reference

13 January 2018

page(s)

727-733

1 reference

13 January 2018

https://scigraph.springernature.com/pub.10.1007/bf03347875

exact match

0 references

cites work

Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism

1 reference

https://api.crossref.org/works/10.1007%2FBF03347875

Drugs interacting with 5-HT systems show promise for treatment of eating disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347875

Open trial of fluvoxamine in the treatment of bulimia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347875

Reduction of feeding behavior by the serotonin uptake inhibitor sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347875

Psychopathology in subgroups of obese women with and without binge eating disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347875

Benefits and limitations of very-low-calorie diet therapy in obese NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347875

Cognitive-behavioural treatments for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347875

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347875

International trial of long-term dexfenfluramine in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347875

Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347875

Use and abuse of appetite-suppressant drugs in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347875

Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347875

Treatment for obesity: a nutrient balance/nutrient partition approach.

21 January 2018

1 reference

12 December 2020

Short cycles of very low calorie diet in the therapy of obese type II diabetes mellitus

1 reference

12 December 2020

Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients

1 reference

12 December 2020

Obese binge eaters: affect, cognitions, and response to behavioural weight control

1 reference

12 December 2020

Very-low-calorie protein diets

1 reference

12 December 2020

Obese people who seek treatment have different characteristics than those who do not seek treatment.

1 reference

12 December 2020

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

1 reference

12 December 2020

d-Fenfluramine selectively suppresses carbohydrate snacking by obese subjects

1 reference

12 December 2020

Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice

1 reference

12 December 2020

Association of binge eating disorder and psychiatric comorbidity in obese subjects.

1 reference

12 December 2020

Feeding pattern studies suggest that d-fenfluramine and sertraline specifically enhance the state of satiety in rats

1 reference

12 December 2020

New perspectives on dietary and behavioural treatments for obesity

1 reference

12 December 2020

A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.

1 reference

12 December 2020

Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression

1 reference

12 December 2020

Serotonin and the biology of feeding

1 reference

12 December 2020

Sensitivity of the appetite control system in obese subjects to nutritional and serotoninergic challenges

1 reference

12 December 2020

A self-rating scale for bulimia. The 'BITE'

1 reference

12 December 2020

Psychopathology correlates of binge eating and binge eating disorder

1 reference

12 December 2020

Behavioral mechanisms for the anorectic action of the serotonin (5-HT) uptake inhibitor sertraline in rats: comparison with directly acting 5-HT agonists.

1 reference

12 December 2020

Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder

1 reference

12 December 2020

A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters

1 reference

12 December 2020

Cognitive treatments for eating disorders

1 reference

12 December 2020

Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03347875

1 reference

13 January 2018

1 reference

13 January 2018